Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85.

There is increasing evidence to implicate a role for CD8(+) T cells in protective immunity against tuberculosis. Recombinant vaccinia (rVV) expressing Mycobacterium tuberculosis (MTB) proteins can be used both as tools to dissect CD8(+) T-cell responses and, in attenuated form, as candidate vaccines capable of inducing a balanced CD4(+)/CD8(+) T-cell response. A panel of rVV was constructed to express four immunodominant secreted proteins of MTB: 85A, 85B and 85C and ESAT-6. A parallel group of rVV was constructed to include the heterologous eukaryotic tissue plasminogen activator (tPA) signal sequence to assess if this would enhance expression and immunogenicity. Clear expression was obtained for 85A, 85B and ESAT-6 and the addition of tPA resulted in N-glycosylation and a 4-10-fold increase in expression. Female C57BL/6 mice were immunised using the rVV-Ag85 constructs, and interleukin-2 and gamma-interferon were assayed using a co-culture of immune splenocytes and recall antigen. There was a marked increase in cytokine production in mice immunised with the tPA-containing constructs. We report the first data demonstrating enhanced immunogenicity of rVV using a tPA signal sequence, which has significant implications for future vaccine design.

[1]  J. Ulmer,et al.  Vaccination with Plasmid DNA Encoding Mycobacterial Antigen 85A Stimulates a CD4+ and CD8+T-Cell Epitopic Repertoire Broader than That Stimulated byMycobacterium tuberculosis H37Rv Infection , 1998, Infection and Immunity.

[2]  P. Andersen,et al.  B-Cell Epitopes and Quantification of the ESAT-6 Protein of Mycobacterium tuberculosis , 1998, Infection and Immunity.

[3]  W. Goebel,et al.  Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I presentation pathway of macrophages. , 1999, Microbes and infection.

[4]  K. Huygen,et al.  H-2-linked control of in vitro gamma interferon production in response to a 32-kilodalton antigen (P32) of Mycobacterium bovis bacillus Calmette-Guérin , 1988, Infection and immunity.

[5]  D. Abramowicz,et al.  Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice , 1992, Infection and immunity.

[6]  C. Harding,et al.  Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. , 1999, Journal of immunology.

[7]  J. Bennedsen,et al.  Proteins released from Mycobacterium tuberculosis during growth , 1991, Infection and immunity.

[8]  M. Horwitz,et al.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Andersen,et al.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins , 1994, Infection and immunity.

[10]  Christopher J. L. Murray,et al.  Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.

[11]  W. Boom,et al.  Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis. , 1997, Journal of immunology.

[12]  A. L. Sørensen,et al.  Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis , 1995, Infection and immunity.

[13]  P. Fine,et al.  Mycobacterial diseases , 1990, The Lancet.

[14]  C. L. Silva,et al.  A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis. , 1994, Immunology.

[15]  M. Chakraborty,et al.  Recurrent Japanese encephalitis epidemics in West Bengal. , 1980 .

[16]  I. Orme,et al.  Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. , 1999, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  E. Paoletti,et al.  Poxvirus-based vectors as vaccine candidates. , 1995, Critical reviews in immunology.

[18]  G. Delogu,et al.  Immunogenicity of DNA Vaccines Expressing Tuberculosis Proteins Fused to Tissue Plasminogen Activator Signal Sequences , 1999, Infection and Immunity.

[19]  S. Kaufmann,et al.  Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I‐ and II‐deficient knock‐out mice: contribution of CD4 and CD8 T cells to acquired resistance , 1995, European journal of immunology.

[20]  F. Elgh,et al.  The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Wiker,et al.  Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. , 1987, Microbial pathogenesis.

[22]  L. Bliss,et al.  Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi , 1992, The Lancet.

[23]  G. Kaplan,et al.  Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice , 1997, Infection and immunity.

[24]  J. Ulmer,et al.  Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. , 1997, Vaccine.

[25]  H. Dockrell,et al.  Role of CD8+ T cells in mycobacterial infections , 2000, Immunology and cell biology.

[26]  A. Malin,et al.  Designing a vaccine for tuberculosis , 1996, BMJ.

[27]  P. Andersen,et al.  Specificity of a protective memory immune response against Mycobacterium tuberculosis , 1993, Infection and immunity.

[28]  H. Dockrell,et al.  Characterization of Human Mycobacterium bovis Bacille Calmette-Guérin-Reactive CD8+T Cells , 1999, Infection and Immunity.

[29]  K. Lukacs,et al.  Protection against Mycobacterium tuberculosisInfection by CD8+ T Cells Requires the Production of Gamma Interferon , 1998, Infection and Immunity.

[30]  S. Kaufmann,et al.  Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Godfrey,et al.  Isoelectrophoretic Characterization of Protein Antigens Present in Mycobacterial Culture Filtrates and Recognized by Monoclonal Antibodies Directed Against the Mycobacterium bovis BCG Antigen 85 Complex , 1992, Scandinavian journal of immunology.

[32]  K. Huygen,et al.  Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG , 1994, Infection and immunity.

[33]  H. Vordermeier,et al.  Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection , 1997, Immunology.

[34]  J. Bennedsen,et al.  Identification of Immunodominant Antigens during Infection with Mycobacterium tuberculosis , 1992, Scandinavian journal of immunology.

[35]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[36]  R. W. Davis,et al.  Dissection of Mycobacterium tuberculosis antigens using recombinant DNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[37]  I. Orme,et al.  T cell response to Mycobacterium tuberculosis. , 1993, The Journal of infectious diseases.

[38]  J. Flynn,et al.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Dockrell,et al.  Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  I. Orme,et al.  The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms , 1997, Infection and immunity.

[41]  N. Haigwood,et al.  Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. , 1991, Nucleic acids research.

[42]  H. Verschueren,et al.  CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A , 2000, European journal of immunology.

[43]  M. Colston,et al.  Vaccination against tuberculosis by DNA injection , 1996, Nature Medicine.

[44]  M. Ashburner A Laboratory manual , 1989 .

[45]  G. Volckaert,et al.  Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis , 1989, Infection and immunity.

[46]  J. De Bruyn,et al.  The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobacterium bovis BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of M. tuberculosis , 1991, Infection and immunity.

[47]  H. Dockrell,et al.  Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro , 1996, Immunology.

[48]  J. Content,et al.  Nucleotide sequence of the 85B-protein gene of Mycobacterium bovis BCG and Mycobacterium tuberculosis. , 1994, DNA sequence : the journal of DNA sequencing and mapping.